Royal Bank of Canada’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $990K | Sell |
33,352
-7,278
| -18% | -$218K | ﹤0.01% | 3626 |
|
|
2025
Q4 | $1.55M | Buy |
40,630
+39,019
| +2,422% | +$1.27M | ﹤0.01% | 3314 |
|
|
2025
Q3 | $38K | Buy |
1,611
+1,137
| +240% | +$21.4K | ﹤0.01% | 5941 |
|
|
2025
Q2 | $7K | Sell |
474
-4,931
| -91% | -$81.7K | ﹤0.01% | 6579 |
|
|
2025
Q1 | $97K | Sell |
5,405
-4,113
| -43% | -$83.5K | ﹤0.01% | 5243 |
|
|
2024
Q4 | $166K | Buy |
9,518
+1,595
| +20% | +$28.2K | ﹤0.01% | 4965 |
|
|
2024
Q3 | $110K | Buy |
7,923
+379
| +5% | +$3.95K | ﹤0.01% | 5277 |
|
|
2024
Q2 | $62K | Buy |
7,544
+3,986
| +112% | +$26.8K | ﹤0.01% | 5547 |
|
|
2024
Q1 | $28K | Sell |
3,558
-19,279
| -84% | -$163K | ﹤0.01% | 5782 |
|
|
2023
Q4 | $205K | Buy |
22,837
+13,151
| +136% | +$95.8K | ﹤0.01% | 5083 |
|
|
2023
Q3 | $87K | Buy |
9,686
+2,031
| +27% | +$28.7K | ﹤0.01% | 5470 |
|
|
2023
Q2 | $117K | Buy |
7,655
+1,732
| +29% | +$31.5K | ﹤0.01% | 5206 |
|
|
2023
Q1 | $133K | Sell |
5,923
-6,817
| -54% | -$145K | ﹤0.01% | 4947 |
|
|
2022
Q4 | $268K | Buy |
12,740
+9,491
| +292% | +$201K | ﹤0.01% | 4627 |
|
|
2022
Q3 | $80K | Sell |
3,249
-2,816
| -46% | -$72.8K | ﹤0.01% | 5464 |
|
|
2022
Q2 | $147K | Sell |
6,065
-48
| -0.8% | -$1.21K | ﹤0.01% | 5044 |
|
|
2022
Q1 | $157K | Sell |
6,113
-6,925
| -53% | -$184K | ﹤0.01% | 5301 |
|
|
2021
Q4 | $405K | Buy |
13,038
+4,732
| +57% | +$133K | ﹤0.01% | 4661 |
|
|
2021
Q3 | $201K | Buy |
8,306
+4,253
| +105% | +$78.1K | ﹤0.01% | 5171 |
|
|
2021
Q2 | $59K | Buy |
4,053
+2,311
| +133% | +$45.6K | ﹤0.01% | 5927 |
|
|
2021
Q1 | $43K | Buy |
1,742
+1,691
| +3,316% | +$46.7K | ﹤0.01% | 5989 |
|
|
2020
Q4 | $1K | Hold |
51
| – | – | ﹤0.01% | 6973 |
|
|
2020
Q3 | $1K | Buy |
51
+32
| +168% | +$622 | ﹤0.01% | 6484 |
|
|
2020
Q2 | $0 | Sell |
19
-170
| -90% | -$2.71K | ﹤0.01% | 6913 |
|
|
2020
Q1 | $3K | Sell |
189
-2,483
| -93% | -$37.4K | ﹤0.01% | 6219 |
|
|
2019
Q4 | $38K | Buy |
+2,672
| New | +$34.1K | ﹤0.01% | 5572 |
|
|
2019
Q3 | – | Sell |
-119
| Closed | -$2K | – | 7129 |
|
|
2019
Q2 | $2K | Sell |
119
-16
| -12% | -$316 | ﹤0.01% | 6604 |
|
|
2019
Q1 | $3K | Hold |
135
| – | – | ﹤0.01% | 6448 |
|
|
2018
Q4 | $3K | Sell |
135
-136
| -50% | -$3.38K | ﹤0.01% | 6366 |
|
|
2018
Q3 | $7K | Buy |
271
+254
| +1,494% | +$7.26K | ﹤0.01% | 6127 |
|
|
2018
Q2 | $0 | Sell |
17
-3,121
| -99% | -$83.1K | ﹤0.01% | 6772 |
|
|
2018
Q1 | $70K | Buy |
3,138
+2,998
| +2,141% | +$71.4K | ﹤0.01% | 4890 |
|
|
2017
Q4 | $3K | Sell |
140
-3,278
| -96% | -$74.9K | ﹤0.01% | 6213 |
|
|
2017
Q3 | $85K | Buy |
3,418
+3,417
| +341,700% | +$75.2K | ﹤0.01% | 5122 |
|
|
2017
Q2 | $0 | Sell |
1
-1,343
| -100% | -$24.4K | ﹤0.01% | 6769 |
|
|
2017
Q1 | $25K | Sell |
1,344
-1,072
| -44% | -$21K | ﹤0.01% | 5518 |
|
|
2016
Q4 | $46K | Buy |
+2,416
| New | +$49.4K | ﹤0.01% | 5308 |
|
|
2016
Q2 | – | Sell |
-850
| Closed | -$12K | – | 6529 |
|
|
2016
Q1 | $12K | Sell |
850
-108
| -11% | -$1.64K | ﹤0.01% | 5676 |
|
|
2015
Q4 | $18K | Sell |
958
-1,544
| -62% | -$30.8K | ﹤0.01% | 5756 |
|
|
2015
Q3 | $50K | Buy |
2,502
+1,652
| +194% | +$48.9K | ﹤0.01% | 5131 |
|
|
2015
Q2 | $28K | Buy |
+850
| New | +$23.3K | ﹤0.01% | 5529 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Royal Bank of Canada's TVTX Position: Q1 2026 in Review
Royal Bank of Canada reduced its Travere Therapeutics (TVTX) stake by 18% in Q1 2026, selling an estimated $218K and leaving 33,352 shares worth $990K. The position accounts for ﹤0.01% of the portfolio, ranked #3626.
Royal Bank of Canada first reported a position in TVTX in Q2 2015 and has held it in 41 quarters since. The position peaked at $1.55M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Royal Bank of Canada held 33,352 shares of Travere Therapeutics worth $990K as of Q1 2026.
- Royal Bank of Canada sold 7,278 Travere Therapeutics shares in Q1 2026, an estimated $218K.
- Travere Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3626 holding.
- Royal Bank of Canada first reported a position in Travere Therapeutics in Q2 2015 and has held it in 41 quarters since.
- Royal Bank of Canada's Travere Therapeutics position peaked at $1.55M in Q4 2025.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.